Practical Approaches for Managing Moderate to Severe Pediatric Atopic Dermatitis: A Pharmacist’s Review of Novel Treatments and Caregiver Counseling Pearls

This activity includes caregiver counseling video vignettes.

Program Description

For children with moderate to severe atopic dermatitis (AD), attaining control of symptoms and avoiding triggers of AD flares are important. Pediatric patients can experience significant impairments to their quality of life, mental development, self-esteem, and physical limitations affecting their ability to engage with peers. The effects of AD can also negatively impact caregivers, so pharmacist involvement in the management of pediatric patients with AD should include counseling for caregivers. Expert panelists will discuss a variety of over-the-counter creams and moisturizers, topical prescription agents, emerging biologics, and other medication classes to equip pharmacists to navigate the options for supportive care and treatment of AD. This activity will also feature counseling videos highlighting novel administration considerations of emerging therapies and the central role of pharmacists in demonstrating proper administration to patients and caregivers as well as counseling on adherence.

Target audience: Specialty pharmacists

Type of activity: Application
Release date: August 11, 2022
Expiration date: October 11, 2022

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Discover the pathogenesis of moderate to severe pediatric atopic dermatitis (AD), the psychosocial impact of disease, and treatment challenges impacting quality of life for both patients and caregivers
• Examine updated guideline-directed pharmacologic and nonpharmacologic treatments for pediatric patients with moderate to severe AD
• Analyze efficacy and safety data, novel mechanisms of action, and routes of administration associated with recently approved and emerging agents for the treatment of moderate to severe pediatric AD
• Customize counseling pearls for patients and caregivers based on individualized treatment plans to improve adherence to new and emerging therapies among pediatric patients with AD

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-331-L01-P. The activity is available for CE credit through October 11, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Anna Fishbein, MD, has the following financial relationships with commercial interests to disclose:

Grant/Research Support: NIH, National Eczema Association, Pfizer

Consultant: Regeneron

Robert J. Kuhn, PharmD, has the following financial relationships with commercial interests to disclose:

Grant/Research Support: Vertex Pharmaceuticals

Jamie L McConaha, PharmD, NCTTP, BCACP, CDCES, and Megan Schneider, BS, PharmD, have no relevant financial relationships with commercial interests to disclose.

Medical Writing and Editorial Support

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: ViiV Healthcare, Janssen, Teratechnologies

Speaker’s Bureau: Merck, Gilead

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle Carlson, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms